...
首页> 外文期刊>Virchows Archiv: an international journal of pathology >Update on lymphoproliferative disorders of the gastrointestinal tract: disease spectrum from indolent lymphoproliferations to aggressive lymphomas
【24h】

Update on lymphoproliferative disorders of the gastrointestinal tract: disease spectrum from indolent lymphoproliferations to aggressive lymphomas

机译:胃肠道淋巴抑制性疾病的更新:从惰性淋巴抑制剂到侵袭性淋巴瘤的疾病谱

获取原文
获取原文并翻译 | 示例

摘要

This paper summarizes two sessions of the workshop during the XIX meeting of the European Association for Haematopathology (EAHP) held in Edinburgh in September 2018 dedicated to lymphomas of the gastrointestinal tract. The first session focused on the clinical and pathological features of primary gastrointestinal T cell and NK-cell lymphoproliferative disorders. The distinction between precursor lesions (RCD type 2) and enteropathy-associated T cell lymphoma were stressed, including the discussion of new diagnostic markers for the identification of aberrant phenotypes. Indolent T cell lymphoproliferative disorders of the gastrointestinal tract cases showed phenotypic heterogeneity with novel molecular alterations in few cases, such as STAT3-JAK2 fusion. In addition, novel clonal markers of disease, such as AXL and JAK3 somatic variants support the neoplastic nature of NK-cell enteropathy. The session on gastrointestinal tract B cell lymphoproliferations was dedicated to B cell lymphoproliferative disorders that arise primarily in the gastrointestinal tract (i.e., duodenal-type follicular lymphoma) or preferentially involve the digestive tract, such as large B cell lymphoma with IRF4 translocation and mantle cell lymphoma (MCL), including diverse molecular subtypes (i.e., CCND3-positive MCL mimicking MALT lymphoma). Challenging cases of high-grade B cell lymphomas with complex genetic profiles demonstrated the usefulness of novel molecular diagnostic methods such as targeted NGS to identify high-risk genetic features with potential clinical impact.
机译:本文总结了在欧洲血吸虫学协会(EAHP)的XIX会议期间在2018年9月举行的胃肠道举行的XIX会议期间,致力于胃肠道的淋巴瘤。第一届会议侧重于原发性胃肠T细胞和NK细胞淋巴抑制性疾病的临床和病理特征。强调前体病变(RCD型2)和肠出疗法相关的T细胞淋巴瘤的区别,包括讨论新诊断标志物,用于鉴定异常表型。胃肠道病例的惰性T细胞淋巴抑制性疾病显示出在少数情况下具有新的分子改变的表型异质性,例如Stat3-Jak2融合。此外,疾病的新型克隆标志物,如AXL和JAK3体躯体变体支持NK细胞肠病的肿瘤性质。胃肠道B细胞淋巴抑制液的会议专用于B细胞淋巴抑制性疾病,主要是胃肠道(即十二指肠型滤泡淋巴瘤)产生或优先涉及消化道,例如具有IRF4易位和地幔细胞的大B细胞淋巴瘤淋巴瘤(MCL),包括不同的分子亚型(即,CCND3阳性MCL模拟麦芽淋巴瘤)。具有复杂遗传型材的高级B细胞淋巴瘤的挑战性案例证明了新型分子诊断方法如靶向NGS的有用性,以鉴定具有潜在临床影响的高危遗传特征。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号